PubMed Health⌕ Search

PubMed · 7894846

Cognitive impairment--is it inevitable?

Abstract

Neuropsychological dysfunction in children and adults with epilepsy is common and has several possible interrelated causes, including the underlying pathophysiology, possible cerebral pathology, the effects of subclinical discharges, sleep disorders, status epilepticus and drug therapy. Of these factors the effects of subclinical discharges and those of medication are potentially remediable. In up to 50% of patients with subclinical epileptiform EEG discharges, these are associated with transitory cognitive impairment. When the discharges are focal, the cognitive deficits usually reflect the normal neuropsychological functions of the affected brain region. Most antiepileptic drugs, with the exception of the benzodiazepines (which themselves adversely affect cognition) and lamotrigine, do not suppress inter-ictal discharges. Although well-designed clinical trials of the effects of antiepileptic drugs are difficult to perform, there is convincing evidence that phenobarbitone and phenytoin cause cognitive impairment. Drugs which control both the seizures and inter-ictal discharges should improve cognitive function, provided the drugs themselves do not have a cognitive penalty. Lamotrigine provides effective control of both overt and subclinical seizures, without adversely affecting cognition.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C D Binnie. 1994. Cognitive impairment--is it inevitable?. https://pubmed.ncbi.nlm.nih.gov/7894846/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗